. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Nat Med. 2014 Apr 6;20(5):548–554. doi: 10.1038/nm.3519

Table 1. Patient characteristics and pre-treatment CAPP-Seq monitoring results.

ND, mutant DNA was not detected above background (see Methods). NA, tumor volume could not be reliably assessed. Dashes, plasma sample not available. Smoking history, ≥20 pack years (Heavy), >0 and <20 pack years (Light). Additional details are provided in Supplementary Table 3 and Supplementary Table 4.

Case	Age	Sex	Histology	Stage	TNM	Smoking history	No. of SNVs (non- silent)	Indels	Fusion		Pre-treatment
Case	Age	Sex	Histology	Stage	TNM	Smoking history	No. of SNVs (non- silent)	Indels	ALK/ROS1	Partner	ctDNA (%)	ctDNA (pg mL⁻¹)	Tumor (cc)
P12	86	F	SCC	IA	T1bN0M0	Heavy	6 (3)	1			ND	ND	5.5

P1	66	M	Adeno	IB	T2aN0M0	Heavy	12 (3)	4			0.025	1.9	23.1

P16	82	F	Adeno	IB	T2aN0M0	Heavy	26 (5)	2			0.019	2.5	22.5

P17	85	F	Adeno	IB	T2aN0M0	Heavy	2 (2)	0			ND	ND	10.2

P13	90	F	SCC	IIB	T3N0M0	Heavy	5 (4)	0			1.78	269.8	339.3

P2	61	M	Large Cell	IIIA	T3N1M0	Heavy	12 (3)	1			0.896	64.7	23.1

P3	67	F	Adeno	IIIB	T1bN3M0	Light	1 (1)	0			0.095	16.2	7.9

P14	55	M	Adeno	IIIB	T1aN3M0	Heavy	8 (5)	0			0.05	10.2	5.2

P15	41	M	Adeno	IIIB	T3N3M0	Light	25 (10)	1			0.58	108.1	121.8

P4	47	F	Adeno	IV	T2aN2M1b	Heavy	3 (2)	0			0.039	2.1	12.4

P5	49	F	Adeno	IV	T1bN0M1a	None	4 (3)	0			3.2	143.8	82.1

P6	54	M	Adeno	IV	T3N2M1b	None	3 (2)	0	ALK	KIF5B	1.0	350.2	NA

P9	49	M	Adeno	IV	T4N3M1a	None	0	0	ALK	EML4	0.04	3.8	66.2
P9	49	M	Adeno	IV	T4N3M1a	None	0	0	ROS1	MKX, FYN	0.04	3.8	66.2

P10	35	F	Adeno	IIIA	T4N0M0	None	0	0	ROS1	SLC34A2	–	–	–

P11	38	F	Adeno	IIIA	T3N2M0	None	2 (1)	0	ROS1	CD74	–	–	–

P7	50	M	Adeno	IV	T1aN2M1b	Light	0	0	ALK	EML4	–	–	–

P8	48	F	Adeno	IV	T4N0M1b	None	1 (0)	0	ALK	EML4	–	–	–